Exelixis Inc (EXEL) - Total Assets
Based on the latest financial reports, Exelixis Inc (EXEL) holds total assets worth $2.84 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Exelixis Inc - Total Assets Trend (1998–2025)
This chart illustrates how Exelixis Inc's total assets have evolved over time, based on quarterly financial data. Also see Exelixis Inc market cap and net worth for the company's overall valuation and market capitalisation.
Exelixis Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Exelixis Inc's total assets of $2.84 Billion consist of 50.7% current assets and 49.3% non-current assets. Review Exelixis Inc total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.0% |
| Accounts Receivable | $286.92 Million | 10.1% |
| Inventory | $21.69 Million | 0.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $63.68 Million | 2.2% |
Asset Composition Trend (1998–2025)
This chart illustrates how Exelixis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See EXEL live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Exelixis Inc's current assets represent 50.7% of total assets in 2025, an increase from 0.0% in 1998.
- Cash Position: Cash and equivalents constituted 17.0% of total assets in 2025, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 10.1% of total assets.
Exelixis Inc Competitors by Total Assets
Key competitors of Exelixis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Exelixis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.56 | 3.63 | 6.72 |
| Quick Ratio | 3.50 | 3.58 | 6.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.04 Billion | $1.06 Billion | $1.22 Billion |
Exelixis Inc - Advanced Valuation Insights
This section examines the relationship between Exelixis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.27 |
| Latest Market Cap to Assets Ratio | 4.28 |
| Asset Growth Rate (YoY) | -3.5% |
| Total Assets | $2.84 Billion |
| Market Capitalization | $12.17 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Exelixis Inc's assets at a significant premium (4.28x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Exelixis Inc's assets decreased by 3.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Exelixis Inc (1998–2025)
The table below shows the annual total assets of Exelixis Inc from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.84 Billion | -3.50% |
| 2024-12-31 | $2.95 Billion | +0.18% |
| 2023-12-31 | $2.94 Billion | -4.20% |
| 2022-12-31 | $3.07 Billion | +17.40% |
| 2021-12-31 | $2.62 Billion | +22.41% |
| 2020-12-31 | $2.14 Billion | +13.35% |
| 2019-12-31 | $1.89 Billion | +32.58% |
| 2018-12-31 | $1.42 Billion | +117.05% |
| 2017-12-31 | $655.29 Million | +9.67% |
| 2016-12-31 | $597.54 Million | +79.80% |
| 2015-12-31 | $332.34 Million | +1.34% |
| 2014-12-31 | $327.96 Million | -34.84% |
| 2013-12-31 | $503.29 Million | -30.21% |
| 2012-12-31 | $721.10 Million | +83.36% |
| 2011-12-31 | $393.26 Million | +9.00% |
| 2010-12-31 | $360.79 Million | +5.06% |
| 2009-12-31 | $343.41 Million | -14.49% |
| 2008-12-31 | $401.62 Million | -2.55% |
| 2007-12-31 | $412.12 Million | +4.22% |
| 2006-12-31 | $395.42 Million | +18.85% |
| 2005-12-31 | $332.71 Million | +14.20% |
| 2004-12-31 | $291.34 Million | -18.57% |
| 2003-12-31 | $357.79 Million | +5.51% |
| 2002-12-31 | $339.11 Million | -2.16% |
| 2001-12-31 | $346.61 Million | +69.15% |
| 2000-12-31 | $204.91 Million | +984.20% |
| 1999-12-31 | $18.90 Million | +110.44% |
| 1998-12-31 | $8.98 Million | -- |
About Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyro… Read more